



### Academic Personnel Short Profile / Short CV

<b>Institution:</b>	The Cyprus Institute of Neurology and Genetics (CING)
<b>Surname:</b>	Patsali
<b>Name:</b>	Petros
<b>Rank/Position:</b>	Associate Scientist
<b>Program of Study:</b>	MSc in Molecular Medicine / MSc in Medical Genetics / MSc in Neuroscience / MSc in Biomedical Research / MSc in Biotechnology / PhD in Molecular Medicine / PhD in Medical Genetics / PhD in Neuroscience
<b>Scientific Domain: *</b>	Genome Editing and Gene Therapy of Thalassaemia

*\*Field of Specialization*

### Academic qualifications / (list by highest qualification)

Qualification	Year	Awarding Institution	Department	Thesis title
PhD	2017	King's College London	Department of Genetics and Molecular Medicine	Advanced personalized gene therapy of $\beta$ -thalassaemia
MSc	2011	Imperial College London	Centre for Neurosciences, Division of Experimental Medicine, Faculty of Medicine	Characterization of HIV-1 lentiviral vectors pseudotyped with Rabies Virus envelope Glycoproteins
BSc	2010	University of Crete	Department of Biology, Faculty of Science and Engineering / Laboratory of Functional Genomics and Aging, FORTH Institute of Molecular Biology and Biotechnology	Production of the plasmid construct 5 'Hom-LoxP- Mms19 Exon1-LoxP-Neo-LoxP-3'Hom and development of a Conditional Knock Out mouse for the gene Mms19



ΔΙΠΑΕ  
CYQAA

ΦΟΡΕΑΣ ΔΙΑΣΦΑΛΙΣΗΣ ΚΑΙ ΠΙΣΤΟΠΟΙΗΣΗΣ ΤΗΣ ΠΟΙΟΤΗΤΑΣ ΤΗΣ ΑΝΩΤΕΡΗΣ ΕΚΠΑΙΔΕΥΣΗΣ  
CYPRUS AGENCY OF QUALITY ASSURANCE AND ACCREDITATION IN HIGHER EDUCATION



eqar /// ENQA

Qualification	Year	Awarding Institution	Department	Thesis title



**Employment history in Academic Institutions/Research Centers – List by the three (3) most recent**

Period of employment		Employer	Location	Position
From	To			
2017	2023	The Cyprus Institute of Neurology and Genetics	Nicosia	Associate Faculty

**Key refereed journal papers, monographs, books, conference publications etc.  
List the five (5) more recent and other five (5) selected –(max total 10)**

Ref. No.	Year	Title	Other authors	Journal and Publisher / Conference	Vol.	Pages
1	2023	High-efficiency editing in hematopoietic stem cells and the HUDEP-2 cell line based on in vitro mRNA synthesis	Papaioannou, N. Y., Patsali, P., Naisseh, B., Papasavva, P. L., Koniali, L., Kurita, R., Nakamura, Y., Christou, S., Sitarou, M., Mussolino, C., Cathomen, T., Kleanthous, M., & Lederer, C. W.	Frontiers in Genome Editing and Frontiers	5	11416 18
2	2022	HBBI VSI-110 (G> A)-specific gene editing as	B Naisseh, NY Papaioannou, P Papasavva, C Lardou, L	HUMAN GENE THERAPY MARY ANN LIEBERT, INC / IUBMB Focused Meeting – Hemoglobin Switching	33	A69- A70

Ref. No.	Year	Title	Other authors	Journal and Publisher / Conference	Vol.	Pages
		advanced therapy for beta-thalassemia	Koniali, M Sitarou, S Christou, CW Lederer, M Kleanthous, P Patsali			
3	2022	Optimisation of mutation-specific TALEN-and CRISPR/Cas9-based gene correction therapy for ss-thalassaemia	P Patsali, PL Papasavva, C Mussolino, NY Papaioannou, S Christou, M Sitarou, MN Antoniou, T Cathomen, CW Lederer, M Kleanthous	HUMAN GENE THERAPY MARY ANN LIEBERT, INC / IUBMB Focused Meeting – Hemoglobin Switching	33	A142-A142
4	2022	CRISPR editing enables consequential tag-activated MicroRNA-mediated endogene deactivation	Panayiota L Papasavva, Petros Patsali, Constantinos C Loucari, Ryo Kurita, Yukio Nakamura, Marina Kleanthous, Carsten W Lederer	International Journal of Molecular Sciences and MDPI	23	1082
5	2021	Distinct miRNA signatures and networks discern fetal from adult erythroid differentiation and primary from immortalized erythroid cells	Panayiota L Papasavva, Nikoletta Y Papaioannou, Petros Patsali, Ryo Kurita, Yukio Nakamura, Maria Sitarou, Soteroulla Christou, Marina Kleanthous, Carsten W Lederer	International Journal of Molecular Sciences and MDPI	22	3626
6	2020	Relative and Absolute Quantification of Aberrant and Normal Splice Variants in HBBIVSI-110 (G > A) $\beta$ -Thalassemia	Petros Patsali, Panayiota Papasavva, Soteroulla Christou, Maria Sitarou, Michael N Antoniou, Carsten W Lederer, Marina Kleanthous	International Journal of Molecular Sciences and MDPI	21	6671



Ref. No.	Year	Title	Other authors	Journal and Publisher / Conference	Vol.	Pages
7	2019	The scope for thalassemia gene therapy by disruption of aberrant regulatory elements	Petros Patsali, Claudio Mussolino, Petros Ladas, Argyro Floga, Annita Kolnagou, Soteroula Christou, Maria Sitarou, Michael N Antoniou, Toni Cathomen, Carsten Werner Lederer, Marina Kleanthous	Journal of Clinical Medicine and MDPI	8	1959
8	2019	Correction of IVS I-110 (G>A) $\beta$ -thalassemia by CRISPR/Cas-and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells	Petros Patsali, Giandomenico Turchiano, Panayiota Papasavva, Marianna Romito, Constantinos C Loucari, Coralea Stephanou, Soteroulla Christou, Maria Sitarou, Claudio Mussolino, Tatjana I Cornu, Michael N Antoniou, Carsten W Lederer, Toni Cathomen, Marina Kleanthous	Haematologica and Ferrata Storti Foundation	104	E497
9	2018	Short-hairpin RNA against aberrant HBBIVSI-110(G>A) mRNA restores $\beta$ -globin levels in a novel cell model and acts as mono- and combination therapy for $\beta$ -thalassemia in primary hematopoietic stem cells	Petros Patsali, Panayiota Papasavva, Coralea Stephanou, Soteroulla Christou, Maria Sitarou, Michael N Antoniou, Carsten W Lederer, Marina Kleanthous	Haematologica and Ferrata Storti Foundation	103	e419



Ref. No.	Year	Title	Other authors	Journal and Publisher / Conference	Vol.	Pages
10	2018	Rapid and sensitive assessment of globin chains for gene and cell therapy of hemoglobinopathies	Constantinos C Loucari, Petros Patsali, Thamar B van Dijk, Coralea Stephanou, Panayiota Papasavva, Maria Zanti, Ryo Kurita, Yukio Nakamura, Soteroulla Christou, Maria Sitarou, Sjaak Philipsen, Carsten W Lederer, Marina Kleanthous	Human gene therapy methods and Mary Ann Liebert, Inc	29	60-74

**Exhibitions (where applicable). List the five (5) more recent and other five (5) selected. (max total 10)**

Ref. No.	Date	Topic	International / Local	Location*	Role in Exhibition
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					

\*Specify venue, geographic location etc

**Research Projects. List the five (5) more recent and other five (5) selected (max total 10)**

Ref. No.	Date	Title	Funded by	Project Role*
1	01/04/2022 – 31/03/2024	Preclinical validation of HBBIVSI-110(G>A)-specific gene editing as advanced therapy for thalassemia (VALID-GT4CY)	RIF Cyprus	Principle Investigator
2	01/08/2019 – 31/07/2022	Personalised Gene Therapy for beta-Thalassaemia (βTHAL-GT4U)	RPF Cyprus	Research Team Member
3	01/11/2012-30/04/2017	THALAssaemia MODular Stratification System for personalized therapy of beta-thalassemia (THALAMOSS)	European Union FP7 research grant	Research Team Member
4	01/09/2012 – 31/08/2014	Advancing Gene Therapy Vectors for Thalassaemia (ΥΓΕΙΑ/ΒΙΟΣ/0311(ΒΕ)/20)	RPF Cyprus	Research Team Member

\*Project Role: i.e. Scientific/Project Coordinator, Research Team Member, Researcher, Assistant Researcher, other

**Academic Consulting Services and/or Participation in Councils / Boards/ Editorial Committees.  
List the five (5) more recent (Optional Entry)**

Ref. No.	Period	Organization	Title of Position or Service	Key Activities
1	2021-2023	Cyprus Society of Human Genetics	Elected Board Member	The Cyprus Society of Human Genetics aims to promote the study and understanding of human genetics in Cyprus and to facilitate the exchange of information and ideas among researchers, clinicians, and other professionals in the field.
2				
3				
4				
5				

**Awards / International Recognition (where applicable). List the five (5) more recent and other five (5) selected.  
(max total 10) (Optional Entry)**

Ref. No.	Date	Title	Awarded by:
1	2019	Panos Ioannou Junior Scientist Award	CING Scientific Council Committee
2	2018	George Stamatoyiannopoulos Award	Hellenic Society of Gene Therapy and Regenerative Medicine
3			
4			
5			
6			
7			
8			



Ref. No.	Date	Title	Awarded by:
9			
10			



**Other Achievements. List the five (5) more recent and other five (5) selected.  
(max total 10) (Optional Entry)**

Ref. No.	Date	Title	Key Activities:
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			